Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Legend Biotech's Enterprise Value is $5,105 Mil.
Legend Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-215 Mil. Therefore, Legend Biotech's EV-to-EBIT ratio for today is -23.78.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Legend Biotech's Enterprise Value is $5,105 Mil.
Legend Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-175 Mil. Therefore, Legend Biotech's EV-to-EBITDA ratio for today is -29.12.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Legend Biotech's Enterprise Value is $5,105 Mil.
Legend Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $1,139 Mil. Therefore, Legend Biotech's EV-to-Revenue ratio for today is 4.48.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Legend Biotech's Enterprise Value is $5,105 Mil.
Legend Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-116 Mil. Therefore, Legend Biotech's EV-to-FCF ratio for today is -44.09.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Legend Biotech (NAS:LEGN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Legend Biotech's current Enterprise Value is $5,105 Mil.
Legend Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-215 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Legend Biotech's current Enterprise Value is $5,105 Mil.
Legend Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-175 Mil.
Legend Biotech's current Enterprise Value is $5,105 Mil.
Legend Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,139 Mil.
Legend Biotech's current Enterprise Value is $5,105 Mil.
Legend Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82 Mil.
Legend Biotech's current Enterprise Value is $5,105 Mil.
Legend Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-116 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech Enterprise Value Related Terms
Legend Biotech Enterprise Value Historical Data
* Premium members only.
The historical data trend for Legend Biotech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LEGN vs DNTH, XENE, CAI: Enterprise Value Comparison
For the Biotechnology subindustry, Legend Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Legend Biotech's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Legend Biotech's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech (LEGN) has a Enterprise Value of $5,105 Mil as of Jun. 28, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Enterprise Value too high?
Legend Biotech's current Enterprise Value is $5,105 Mil. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Enterprise Value compare to DNTH and XENE?
Legend Biotech's Enterprise Value of $5,105 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Legend Biotech and its competitors. Legend Biotech's current Enterprise Value is $5,105 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $98.55, compared to a current price of $28.70 — trading 70.9% below its estimated fair value. The current Enterprise Value is $5,105 Mil. Legend Biotech's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Enterprise Value is $5,105 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $28.70 is trading 70.9% below its estimated GF Value™ of $98.55.
GuruFocus considers Legend Biotech to be Possible Value Trap.
Key valuation signals for LEGN:
Enterprise Value: $5,105 Mil
GF Value™: $98.55 vs. price of $28.70 (70.9% below fair value)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score
Get the complete analysis for LEGN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
